United Therapeutics (NASDAQ:UTHR) released its quarterly earnings data on Wednesday. The biotechnology company reported $2.42 earnings per share for the quarter, missing analysts’ consensus estimates of $3.23 by ($0.81), MarketWatch Earnings reports. United Therapeutics had a return on equity of 34.42% and a net margin of 40.87%. The company had revenue of $412.70 million for the quarter, compared to analyst estimates of $378.22 million. During the same period in the previous year, the business posted $4.69 EPS. The firm’s revenue for the quarter was down 7.4% compared to the same quarter last year.
NASDAQ:UTHR opened at $115.04 on Friday. United Therapeutics has a 1-year low of $100.57 and a 1-year high of $152.55. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.35 and a current ratio of 4.64. The firm has a market capitalization of $5.34 billion, a P/E ratio of 10.56, a PEG ratio of 27.68 and a beta of 1.21.
A number of analysts have weighed in on UTHR shares. Wedbush raised their price objective on shares of United Therapeutics from $234.00 to $253.00 and gave the stock an “outperform” rating in a report on Thursday, August 2nd. TheStreet cut shares of United Therapeutics from a “b” rating to a “c+” rating in a report on Thursday, September 6th. BidaskClub cut shares of United Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, September 24th. Standpoint Research raised shares of United Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, October 12th. Finally, Zacks Investment Research cut shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 22nd. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. United Therapeutics presently has a consensus rating of “Hold” and an average price target of $137.71.
In other United Therapeutics news, Director Christopher Causey sold 810 shares of the business’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $118.00, for a total transaction of $95,580.00. Following the sale, the director now directly owns 3,925 shares in the company, valued at approximately $463,150. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard Giltner sold 3,240 shares of the business’s stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $129.38, for a total transaction of $419,191.20. The disclosure for this sale can be found here. Over the last quarter, insiders sold 4,860 shares of company stock worth $611,161. 8.20% of the stock is currently owned by insiders.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Article: Preferred Stock
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.